Charles River Launches New Retrogenix® Non-Human Protein Library
First-in-class in vitro library assesses off-target binding to de-risk in vivo studies
“Developed in-house using the innovative and unique Retrogenix® platform, the new library provides early insights into how therapeutics interact with non-human protein targets in vitro,” said
Confirming whether potential off-targets are conserved across species increases the interpretability of in vivo results and ultimately reduces risk by ensuring safety studies are conducted in an appropriate model from the outset. In addition to offering the non-human protein library, Charles River can also screen observed human off-targets against any suitable non-human homologous proteins to help inform next steps for client drug development.
Screening for Off-Target Effects
The Retrogenix® platform offers the industry’s largest library of human proteins overexpressed in human cells, with over 6,500 human plasma membrane and secreted protein clones, providing a unique screening tool for discovering primary target receptors and reliably assessing potential off-target binding issues. With the new non-human protein library, Charles River is building on the Retrogenix® platform’s established technology, helping clients ensure they have the right models selected prior to beginning in vivo studies, saving time and helping deliver safer, more effective drugs.
Off-target screening is an established part of the IND submission process, and is traditionally performed using tissue cross reactivity (TCR) studies. Data from the Retrogenix® platform has become an established complementary or alternative data point across multiple modalities, therapeutic areas, and with international regulatory agencies.
Driving Innovation in the
Designed in silico and synthetically generated, the biosynthetic non-human protein library incorporates important tenants of the 3Rs—reduction and refinement—leveraging technological innovations to responsibly progress research.
“The integration of the Retrogenix®
Building on the imperative to deliver on the
About the
The
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241017338853/en/
Investor:
Corporate Vice President,
Investor Relations
781.222.6455
todd.spencer@crl.com
Media:
Corporate Vice President,
Chief Communications Officer
781.222.6168
amy.cianciaruso@crl.com
Source: